TEVA PHARMACEUTICAL FIN LLC's ticker is and the CUSIP is 88163VAE9. A total of 52 filers reported holding TEVA PHARMACEUTICAL FIN LLC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $10,013,000 | -8.5% | 9,964,000 | -10.7% | 0.17% | -27.7% |
| Q3 2020 | $10,942,000 | -27.2% | 11,160,000 | -27.4% | 0.24% | -28.7% |
| Q2 2020 | $15,034,000 | +26.5% | 15,366,000 | +20.3% | 0.33% | 0.0% |
| Q1 2020 | $11,883,000 | -4.1% | 12,771,000 | -1.8% | 0.33% | +43.3% |
| Q4 2019 | $12,389,000 | +290.9% | 13,001,000 | +273.6% | 0.23% | +275.8% |
| Q3 2019 | $3,169,000 | -54.1% | 3,480,000 | -53.7% | 0.06% | -51.9% |
| Q2 2019 | $6,907,000 | -46.3% | 7,511,000 | -45.9% | 0.13% | -47.1% |
| Q1 2019 | $12,863,000 | -83.7% | 13,878,000 | -84.0% | 0.24% | -66.0% |
| Q4 2018 | $78,756,000 | +399.8% | 86,786,000 | +418.0% | 0.72% | +238.7% |
| Q3 2018 | $15,756,000 | -3.8% | 16,755,000 | -4.7% | 0.21% | -7.4% |
| Q2 2018 | $16,379,000 | +17.5% | 17,577,000 | +11.1% | 0.23% | +3.6% |
| Q1 2018 | $13,944,000 | +10.5% | 15,820,000 | +10.6% | 0.22% | +11.6% |
| Q4 2017 | $12,624,000 | – | 14,305,000 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ZAZOVE ASSOCIATES LLC | 83,413,000 | $130,650,000 | 6.13% |
| AEGON USA Investment Management, LLC | 6,000,000 | $9,368,000 | 2.35% |
| MACKAY SHIELDS LLC | 24,370,000 | $38,152,000 | 2.07% |
| INCOME RESEARCH & MANAGEMENT | 4,374,000 | $6,829,000 | 1.11% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 20,000 | $20,347,000 | 0.99% |
| SHENKMAN CAPITAL MANAGEMENT INC | 5,269,000 | $8,264,000 | 0.82% |
| Mitsubishi UFJ Securities Holdings Co., Ltd. | 325,000 | $511,000 | 0.76% |
| PALISADE CAPITAL MANAGEMENT, LP | 9,299,000 | $14,598,000 | 0.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 14,543,000 | $23,021,000 | 0.35% |
| CSS LLC/IL | 3,750,000 | $5,893,000 | 0.35% |